BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)

Zhan Ye  1     Li Xi  1     Anindita Banerjee  1     Padmalatha Reddy  1     Engin Altintas  2     Jacek Romatowski  3     Jaroslaw Leszczyszyn  4     Silvio Danese  5     William Sandborn  6     Christopher Banfield  6     Jeremy Gale  6     Elena Peeva  6     Michael Vincent  6     Craig L. Hyde  6     Randy Longman  7     Kenneth Hung  7     Mina Hassan-Zahraee  7    
1 Pfizer Inc., Cambridge, United States
2 Mersin University, Mersin, Turkey
3 Provincial Complex Hospital, Bialystok, Poland
4 Melita Medical Center, Wroclaw, Poland
5 IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
6 University of California San Diego, La Jolla, United States
7 Weill Cornell Medicine, New York, United States

Topic
IBD, Immunology, Nurses

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing